Dapagliflozin Mitigates Renal Fibrosis and Inflammation in Obese 5/6‐Nephrectomized Rats
FASEB BioAdvances · 2026-11 · 8 (11)
DOI: 10.1096/fba.2026-00199 ↗Kurz gefasst
Fachartikel in der Zeitschrift FASEB BioAdvances, online erschienen am 15.11.2026. Verfasst von Desiree Rita Denelle Bernardo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Investigacao Medica 12 (LIM12), Faculdade de Medicina Universidade de São Paulo São Paulo Brazil. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo.
Abstract (Originalsprache)
Obesity is a chronic disease directly and indirectly related to the progression of chronic kidney disease. Sodium‐glucose cotransporter‐2 inhibitors like dapagliflozin offer new renal protection strategies beyond their glucose‐lowering properties. This study evaluated the effects of dapagliflozin on kidney impairment in obese rats subjected to 5/6 nephrectomy. Male Wistar rats (8 weeks old) were followed during a 100‐day protocol and submitted to Nx surgery on Day 40. The animals were randomly allocated to four groups according to the diet: standard (Nx); high‐fat (Nx + H); standard + dapagliflozin (Nx + D); and high‐fat +dapagliflozin (Nx + H + D). Dapagliflozin (50 mg/kg diet) treatment was administered daily after Nx surgery. Assessments included anthropometrics, inulin clearance, renal hemodynamics, biochemistry, immunohistochemistry, and protein expression for inflammation and fibrosis. Dapagliflozin treatment led to reduced body weight and abdominal circumference in the Nx + H + D. It also increased glycosuria and lowered plasma glucose. Crucially, dapagliflozin restored glomerular filtration rate and attenuated the renal expression of extracellular matrix proteins, inflammatory markers, and phenotypic alterations. This resulted in a lower kidney injury score compared to the Nx + H. In summary, dapagliflozin attenuated metabolic and anthropometric parameters and mitigated the progression of kidney disease in obese rats following a 5/6 nephrectomy insult.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratorio de Investigacao Medica 12 (LIM12), Faculdade de Medicina Universidade de São Paulo São Paulo Brazil.
- Laboratorio de Investigacao Medica 12 (LIM12), Faculdade de Medicina, Hospital das Clinicas HCFMUSP Universidade de São Paulo São Paulo Brazil.
- Department of Physiology, Ribeirão Preto Medical School University of São Paulo Ribeirão Preto Brazil.
ORCID-Profile: Desiree Rita Denelle Bernardo, Ana Carolina de Bragança, Rildo Aparecido Volpini
Förderung
- Fundação de Amparo à Pesquisa do Estado de São Paulo
Zitieren
APA
Bernardo, D. R. D., Canale, D., Nascimento, M. M., Shimizu, M. H. M., Seguro, A. C., de Bragança, A. C., & Volpini, R. A. (2026). Dapagliflozin Mitigates Renal Fibrosis and Inflammation in Obese 5/6‐Nephrectomized Rats. FASEB BioAdvances, 8(11). https://doi.org/10.1096/fba.2026-00199
Vancouver
Bernardo DRD, Canale D, Nascimento MM, Shimizu MHM, Seguro AC, de Bragança AC, et al. Dapagliflozin Mitigates Renal Fibrosis and Inflammation in Obese 5/6‐Nephrectomized Rats. FASEB BioAdvances. 2026;8(11). doi:10.1096/fba.2026-00199
BibTeX
@article{Bernardo2026,
author = {Bernardo, Desiree Rita Denelle and Canale, Daniele and Nascimento, Mariana Moura and Shimizu, Maria Heloisa Massola and Seguro, Antonio Carlos and de Bragança, Ana Carolina and Volpini, Rildo Aparecido},
title = {Dapagliflozin Mitigates Renal Fibrosis and Inflammation in Obese 5/6‐Nephrectomized Rats},
journal = {FASEB BioAdvances},
year = {2026},
volume = {8},
number = {11},
doi = {10.1096/fba.2026-00199}
}
EUVIMED